Nóra Baligács

Nóra Baligács

Auto-generated profile, based on publicly available information

Nóra Baligács

VIB Centre for Brain & Disease Research, Department of Neurosciences, Leuven Brain Institute

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
NBNóra Baligács
Nóra Baligács
GAGiulia Albertini
Giulia Albertini
SBSarah C. Borrie
Sarah C. Borrie
LSLutgarde Serneels
Lutgarde Serneels
CPClare Pridans
Clare Pridans
BSBart De Strooper
Bart De Strooper
The role of microglia in the amyloid cascade of Alzheimer’s disease (AD) is debated due to conflicting findings. Using a genetic and a pharmacological approach we demonstrate that depletion of microglia before amyloid-β (Aβ) plaque deposition, leads to a reduction in plaque numbers and neuritic dystrophy, confirming their role in plaque initiation. Transplanting human microglia restores Aβ plaque formation. While microglia depletion reduces insoluble Aβ levels, soluble Aβ concentrations stay consistent, challenging the view that microglia clear Aβ. In later stages, microglial depletion decreases plaque compaction and increases neuritic dystrophy, suggesting a protective role. Human microglia with the TREM2R47H/R47H mutation exacerbate plaque pathology, emphasizing the importance of non-reactive microglia in the initiation of the amyloid cascade. Adaptive immune depletion (Rag2-/-) does not affect microglia’s impact on plaque formation. These findings clarify conflicting reports, identifying microglia as key drivers of amyloid pathology, and raise questions about optimal therapeutic strategies for AD.

8 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NBNóra Baligács
Nóra Baligács
GAGiulia Albertini
Giulia Albertini
SBSarah C. Borrie
Sarah C. Borrie
LSLutgarde Serneels
Lutgarde Serneels
CPClare Pridans
Clare Pridans
BSBart De Strooper
Bart De Strooper
We demonstrate the dual role of microglia in Alzheimer’s disease (AD), initially harmful, by seeding amyloid plaques, and protective in later stages by compacting amyloid plaques. Early microglial depletion using pharmacological or genetic blockage of CSF1R reduces plaque load and associated neuritic dystrophy, while human microglia transplantation restores plaque formation, confirming their seeding role. Transplanted TREM2 R47H/R47H microglia exacerbate plaque pathology, highlighting microglia as key initiators of the amyloid pathology cascade.

2 March 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
KKKaterina Konstantoulea
Katerina Konstantoulea
MRMeine Ramakers
Meine Ramakers
SBSarah C. Borrie
Sarah C. Borrie
DTDries T’SYen
Dries T’SYen
DMDaan Moechars
Daan Moechars
Joost SchymkowitzJoost Schymkowitz
Joost Schymkowitz
The prevailing view frames microglia and macrophages as guardians against amyloid beta (Aβ) accumulation in Alzheimer’s disease (AD). Here, we overturn this paradigm by demonstrating that human phagocytic cells, including differentiated THP-1 macrophages and hESC-derived microglia, are not merely passive responders but active producers of extracellular, seeding-competent Aβ42 fibrils, the amyloid species most strongly linked to parenchymal plaque formation and neurodegeneration. These cell-generated aggregates differ structurally and functionally from synthetic fibrils, displaying enhanced seeding and tau cross-seeding activity in biosensor models. Notably, Aβ42 fibril formation in this system requires active cellular processes and is exacerbated by loss of Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), a major AD risk gene. Transcriptomic profiling reveals an early inflammatory response resembling microglial states observed in human AD models. Together, these findings support emerging evidence from in vivo studies that macrophages and microglia can influence amyloid seeding and introduce a human-relevant in vitro platform to explore how Aβ aggregation intersects with innate immune function and genetic risk. Our results reinforce the concept that microglia may play a dual role in AD, acting both as responders and inadvertent facilitators of amyloid assembly, with implications for early therapeutic intervention.

17 June 2026 in Research Square
Verified
Preprint
Open access
BSBart De Strooper
Bart De Strooper
JVJacqueline Vierbergen
Jacqueline Vierbergen
SBSriram Balusu
Sriram Balusu
KHKatrien Horré
Katrien Horré
NBNóra Baligács
Nóra Baligács
PVPatrik Verstreken
Patrik Verstreken
The pathological cascade of Alzheimer's disease (AD) begins decades before clinical symptoms, yet modelling this slow and progressive process in experimental systems has remained challenging. Current models largely depend on Tau mutations associated with primary Tauopathies and fail to reproduce AD-relevant neurofibrillary tangle formation, even when human Tau isoforms and amyloid pathology are combined. Here, we xenotransplanted human neurons into Rag2 −/− and Rag2 −/− App NL−G−F mice and exposed them to AD-derived Tau seeds via parenchymal brain injections, providing both the pathological nucleation event and the amyloid-rich environment needed to compress decades of human disease into the lifespan of a mouse. Whilst AD-Tau seeding alone was sufficient to induce Tau misfolding in human neurons, amyloid exposure markedly accelerated Tau aggregation, driving neurofibrillary tangle formation and elevated insoluble pTau181 and pTau231 in aged xenografts. This effect was abolished in human Tau-knockout neurons, although LAMP1 positive neuritic dystrophy persisted. Late-stage Tau pathology was absent in non-grafted App NL−G−F mice, indicating a unique human neuronal susceptibility to Tau aggregation. Together, these findings demonstrate that the human neuronal environment is a critical determinant of neurofibrillary tangle formation, and that amyloid causally accelerates this process, thereby establishing the Tau seeded xenograft model as a platform to dissect the interaction between amyloid and Tau in a human-relevant system.